Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) shares passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $10.28 and traded as high as $10.55. Eliem Therapeutics shares last traded at $10.33, with a volume of 688,983 shares trading hands.
Eliem Therapeutics Stock Performance
The company has a market cap of $304.96 million, a P/E ratio of -19.34 and a beta of -0.39. The firm has a 50 day moving average price of $12.74 and a two-hundred day moving average price of $10.28.
Eliem Therapeutics Company Profile
Eliem Therapeutics, Inc is a biopharmaceutical company that historically focused on developing therapies for disorders associated with abnormal neuronal excitability, including neuropathic pain, epilepsy, depression, and anxiety. The company’s research programs were designed to address conditions affecting the central and peripheral nervous systems.
Eliem’s development pipeline included ETX-810, an oral prodrug of pregabalin intended to improve the delivery and therapeutic profile of an established treatment for neuropathic pain, and ETX-155, a GABA-A receptor positive allosteric modulator investigated for potential use in neurological and psychiatric disorders.
Featured Articles
- Five stocks we like better than Eliem Therapeutics
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
